CTI BioPharma Corp (CTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione that is used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in Europe and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.
CTI BioPharma Corp Key Recent Developments
Mar 02,2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 27,2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
Jan 24,2017: CTI Biopharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
Dec 01,2016: CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
Nov 08,2016: CTI BioPharma Reports Third Quarter 2016 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
CTI BioPharma Corp - Key Facts 6
CTI BioPharma Corp - Key Employees 7
CTI BioPharma Corp - Key Employee Biographies 8
CTI BioPharma Corp - Major Products and Services 10
CTI BioPharma Corp - Pharmaceutical Pipeline Products Data 11
CTI BioPharma Corp, Pipeline Products by Therapy Area 11
CTI BioPharma Corp, Pipeline Products by Development Phase 11
CTI BioPharma Corp - History 13
CTI BioPharma Corp - Company Statement 16
CTI BioPharma Corp - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Section 2 – Company Analysis 19
CTI BioPharma Corp - Business Description 19
CTI BioPharma Corp - Corporate Strategy 20
CTI BioPharma Corp - SWOT Analysis 21
SWOT Analysis - Overview 21
CTI BioPharma Corp - Strengths 21
CTI BioPharma Corp - Weaknesses 22
CTI BioPharma Corp - Opportunities 23
CTI BioPharma Corp - Threats 24
CTI BioPharma Corp - Key Competitors 25
Section 3 – Company Financial Ratios 26
Financial Ratios - Capital Market Ratios 26
Financial Ratios - Annual Ratios 27
Performance Chart 29
Financial Performance 29
Financial Ratios - Interim Ratios 30
Financial Ratios - Ratio Charts 31
Section 4 – Company’s Lifesciences Financial Deals and Alliances 32
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33
CTI BioPharma Corp, Recent Deals Summary 34
Section 5 – Company’s Recent Developments 35
Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 35
Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 37
Jan 24, 2017: CTI Biopharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors 38
Dec 01, 2016: CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 39
Nov 08, 2016: CTI BioPharma Reports Third Quarter 2016 Financial Results 40
Oct 03, 2016: CTI BioPharma Announces Retirement Of President And CEO 41
Aug 04, 2016: CTI BioPharma Reports Second Quarter 2016 Financial Results 42
May 10, 2016: CTI BioPharma Reports First Quarter 2016 Financial Results 43
Feb 16, 2016: CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results 44
Jan 13, 2016: CTI BioPharma Appoints Matthew Perry To Board Of Directors 46
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51List of Tables
CTI BioPharma Corp, Key Facts 6
CTI BioPharma Corp, Key Employees 7
CTI BioPharma Corp, Key Employee Biographies 8
CTI BioPharma Corp, Major Products and Services 10
CTI BioPharma Corp, Number of Pipeline Products by Development Stage 12
CTI BioPharma Corp, History 13
CTI BioPharma Corp, Subsidiaries 18
CTI BioPharma Corp, Key Competitors 25
CTI BioPharma Corp, Ratios based on current share price 26
CTI BioPharma Corp, Annual Ratios 27
CTI BioPharma Corp, Annual Ratios (Cont...1) 28
CTI BioPharma Corp, Interim Ratios 30
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33
CTI BioPharma Corp, Recent Deals Summary 34
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50List of Figures
CTI BioPharma Corp, Pipeline Products by Therapy Area 11
CTI BioPharma Corp, Pipeline Products by Development Phase 11
CTI BioPharma Corp, Performance Chart (2012 - 2016) 29
CTI BioPharma Corp, Ratio Charts 31
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 33
Puma Biotechnology Inc
Orexigen Therapeutics Inc
Oncogenex Pharmaceuticals Inc
Incyte Corp
Geron Corp
Clovis Oncology Inc
Array BioPharma Inc
Ariad Pharmaceuticals Inc
